PTLA—There’s nothing wrong with Betrixaban per se, but it’s not differentiated from Eliquis (or Xarelto) and it’s very late to market even in the best-case scenario. That’s why MRK pulled out of the partnership to develop Betrixaban two years ago (#msg-61300408).
If PTLA would scrap Betrixaban and focus only on extracting maximum value for PRT-4445, I would be more inclined to invest.
News 
Market Data 
Discover 
